Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Stock photo

Thinkstock

Doctors should think twice about prescribing drugs like Ritalin and Adderall used to treat attention deficit disorder to healthy individuals seeking to boost their brain power, says an article in this weeks edition of the Canadian Medical Association Journal.

The authors say prescription stimulants are used by some people for cognitive enhancement in the absence of any medical need.

"These would be any types of medications that would help people enhance their concentration, memory, cognitive function in general, when they don't necessarily have any type of symptom or illness to be treated with these medications," said lead author Cynthia Forlini, a PhD candidate in neuroethics at McGill University.

Story continues below advertisement

"So we're talking about healthy individuals who are approaching their doctors for some kind of an edge in their performance," she said.

There is little data in Canada on how widespread the practice is, but some studies suggest that 1 to 11 per cent of university students take cognitive-enhancing medications, obtaining them through peers or black-market channels.

"So we can't say exactly how big of a problem this is, but it is nonetheless something that needs to be considered from a physician's point of view."

Forlini and her co-authors argue there are several reasons why doctors should avoid prescribing ADD drugs to patients who do not have symptoms of attention deficit disorder or related conditions.

For one, it is unclear whether the medications confer any benefit – and their side effects may cause harm. "There isn't a lot of evidence to suggest that these medications actually work for healthy individuals," Forlini said, noting that while some studies have shown modest effects, much of the evidence has been anecdotal.

"But there's no kind of resounding call to say this is something that is supported by scientific data."

Dr. David Juurlink, head of clinical pharmacology and toxicology at the Sunnybrook Health Sciences Centre in Toronto, said the potential harm associated with the drugs is important for doctors – and patients – to consider.

Story continues below advertisement

"For the most part, these drugs are chemically similar to amphetamines and … these drugs are expected to share some side effects with amphetamines," he said. "And those would include, but are not limited to, increased blood pressure, increased risk of stroke and myocardial infarction [heart attack], psychosis and insomnia, as well as the potential risk of addiction."

The authors suggest that prescribing cognitive enhancers to healthy people is not a good use of resources under Canada's publicly funded health-care system.

Forlini said resources should be allocated to "people who need them and not necessarily just to people who can afford them or people who might not necessarily need them."

Indeed, at certain points during the ongoing drug shortage, some people diagnosed with ADD were unable to obtain the prescription medications they needed, she said.

Doctors, whether neurologists, psychiatrists or general practitioners, have a "stewardship" responsibility to distribute health-care resources in an appropriate manner, the authors stress.

While guidelines by the American Academy of Neurology say doctors can prescribe these drugs to patients without an ADD diagnosis, they are neither ethically obliged nor ethically prohibited to do so when asked by a patient.

Story continues below advertisement

"What we want to say to physicians is that they should seriously consider all of the aspects … when faced with requests," Forlini said. "In the end, the conclusion might be that they should not be prescribing.

"So there is a difference here between can and should, where one is permission but the others draw upon responsibilities that physicians may have that go beyond whether they can or can't do something."

Juurlink agrees with the authors' conclusion that care needs to be taken when considering "off-label" uses for ADD drug.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies